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Palliative care privileges comfort over healing, with the 
main intent on management of symptoms such as pain or 
bleeding. Usually palliative cares are reserved for patients 
with a diagnosis of terminal illness with less than 6-month 
life expectancy when the curative treatments are no longer 
possible (1). 
Palliative care has been studied in many types of cancer, 
demonstrating a consistent improvement in quality of life 
(QoL) (2,3). Its role in management of patients with bladder 
cancer is still controversial, even if these patients, especially 
those with locally advanced disease, present persistent 
symptoms that dramatically affect their QoL.  
In a recent published study by Hugar et al. the use of 
palliative care in muscle invasive bladder cancer (MIBC) 
resulted to be quite limited in the USA, with less than 4% 
of patients receiving any kind of supportive treatment, 
regardless of solid proof for integrating its utilization into 
standard oncological care (4). This fact could be explained 
by the lack of dedicated guidelines and the presence of 
only general palliative care guidelines from the European 
Association of Urology (5). 
Understanding palliative care use in MIBC patients is 
becoming crucial within identifying those who might likely 
benefit the most.
In the 20–30% of patients who have potentially fatal 
MIBC, we have to distinguish two categories of patients: 
those with potentially curable disease but considered 
too frail to undergo radical treatments (such as radical 
cystectomy or trimodality treatment), and others with a 
disease stage too advanced to offer curative treatment. Both 
populations however, suffer from severe local symptoms 
from their disease, with hematuria, and dysuria irritative 
bladder, which possibly require help for the duration of 
their survival (6). 
Palliative pelvic radiotherapy (PRT) plays a role in these 
symptoms management and in local control of disease (7). 
Ali et al. published a study aiming to investigate the 
efficacy of PRT in patients with bladder cancer and to 
identify factors associated with treatment outcome (8). The 
authors pointed out the very important question of selection 
in order to identify patients who really can have a benefit 
with PRT. 
This retrospective analysis included 241 patients with 
a diagnosis of MIBC at different stages, treated with 
conventional 3D conformal radiotherapy (3D CRT). 
Median age was of 80 years (range, 41–97). A treatment was 
considered “futile” when a patient died within 30 days since 
PRT completion or was not able to complete the course 
of treatment. The median overall survival (mOS), from 
the end of RT to death by any cause, was 5 months (95% 
CI: 4.4–6.2), with 20.3% of patients surviving longer than 
12 months (1 in 5 patients).  
The mOS were 3.7 months (95% CI: 1.7–6.3) and 
3.2 months (95% CI: 2.5–4.8) for locally advanced (stage 
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III) and late stage (stage IV, recurrence), respectively. 
Following the multivariate analysis, longer survival were 
associated with ECOG PS ≤2, earlier stage of disease (stage 
≤II) and higher ACE-27 score (≥2). ACE-27 score was a 
27-item validated comorbidity index for use with cancer 
patients (8). So, patient-related factors were assumed to 
have a greater impact on potential treatment benefit.
An important consideration should be done about the 
symptoms control, at the end of RT 75% (150 of 200) of 
alive patients were symptomatic, and 53% among them 
(80 of 150) experienced an improvement after treatment 
in hematuria, in local symptoms (i.e., urinary frequency 
and dysuria) and pain score (54.1%, 56.8% and 47.6%, 
respectively).Therefore the effect of PRT was not 
immediate.
The 30-day mortality after PRT was 18% (44 patients). 
A further 7% (17 patients) died before completing planned 
PRT and another 7% (16 patients) did not complete PRT 
as prescribed. 
In conclusion, good performance status patients with 
earlier stage disease and few comorbidities survived longer 
and PRT was an effective, well-tolerated treatment. Thus, 
for preventing futile treatment, comprehensive assessment 
and patient selection are crucial.
For what concerns RT schedule there was a quiet wide 
range of used doses, from 8 Gy/1 Fr to 30 Gy/10 Fr. 
Hypofractionated schemes such as 21 Gy/3 Fr or 20 Gy/5 Fr 
were also employed. Interestingly, no correlation between 
the RT schedule and clinical outcomes was found. 
If there is limited literature about the use of PRT and 
reporting bladder cancer outcomes, even more uncertain 
appears the optimal schedule of RT in advanced MIBC. All 
the available data derive from retrospective studies and from 
one multicenter randomized trial. MRC BA09 is the largest 
randomized trial for patient with bladder cancer undergoing 
PRT. It enrolled 500 patients considered unsuitable for 
curative treatment according to their disease stage or 
comorbidity, comparing to RT schedules: 35 Gy/10 Fr 
and 21 Gy/3 Fr (7). First endpoint of the study was to 
evaluate symptomatic improvement after treatment. Change 
in Bladder- or bowel-related symptoms, from pre and post 
RT treatment, showed no evidence of differences between 
the treatment arms. Moreover, no difference in survival 
between the two schedules was evidenced. 
Different PRT protocols are still being used, despite 
these results, and the dose choice depends on clinicians’ 
experience and preference. 
What seems clear in this highly palliative setting is 
that hypofractionation is a reasonable option in order to 
increase patient comfort (reducing the time traveling to the 
hospital). Moreover, the hemostatic effect of RT is seen 
after few fractions and often intractable hematuria is the 
main symptom in these patients. The disadvantage of the 
most common hypofractionated schedules (5 Gy ×4, 8 Gy 
×4 or 13 Gy ×3 once daily) is the higher risk  of toxicity, 
considering the complexity of the pelvic region and the 
sensitivity of the bladder itself (9). Therefore, different 
alternative schedules were studied, such as hypofractionated 
radiation schedule with a once weekly treatment. The 
rationale of this approach is to potentially permit a recovery 
from the acute toxicity, but the main drawback could 
be the tumor repopulation resulting in a less effective 
treatment and a worse local control (10). Indeed, several 
studies supported to spreading the dose over 5–6 weeks, 
with good clinical outcome and lower toxicity compared to 
conventional treatment (11,12). More recent data confirmed 
that the Overall Treatment Time (OTT) does not impact 
the treatment efficacy of RT in bladder cancer (13). It has to 
be noticed that in the majority of these studies the planning 
target volume (PTV) was obtained by expanding the clinical 
target volume (CTV), corresponding to the whole bladder, 
with a margin of 1–2 cm. The technique used was 3D CRT. 
The whole bladder is conventionally considered as the 
target volume due to the difficulties in tumor localization, 
in the accuracy of treatment delivery, and because bladder 
cancer is usually multifocal. Despite that, targeting treatment 
to the tumor might give equivalent local control (14), as 
showed by brachytherapy data, and retrospective data too 
suggest that bladder healthy tissue sparing reduced the 
toxicity risk (15). 
The reports on reduced bladder volume receiving high-
dose radiation regards mostly the use of RT in MIBC 
for curative intent in a multimodality setting. The data 
published in the randomized non-inferiority trial of the 
BC2001 Trial (CRUK/01/004) showed equivalent outcomes 
with partial- and whole-bladder irradiation and even 
reported trends toward improved local control and survival 
with partial-bladder treatment (16).
Since these earlier studies, radiation and imaging 
techniques have evolved. The introduction of both 
intensity-modulated radiation therapy (IMRT) and image-
guided RT (IGRT), has improved conformity of the 
radiation dose to the target volume and a reduction of the 
gastrointestinal and genitourinary toxicity (17). 
Stereotact ic  body radiotherapy (SBRT) is  a lso 
emerging as an option in treating macroscopic disease in 
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oligometastatic urothelial cancer with encouraging results 
in terms of oncological outcome and with acceptable 
toxicity (18,19). Indeed, these two unique Italian series 
using extremely conformal RT modality (SBRT) to limited 
volume oligorecurrent/oligometastatic MIBC (including 
local recurrence) showed local control rate at 1 year after 
SBRT of 70%. Only single acute or late low-grade toxicity 
events were registered.  
Bladder cancer cells showed to have a lower alpha-beta 
ratio very close normal tissues one, according to in vitro 
data. The low alpha-beta ratio of bladder cancer could 
provide a radiobiological explanation for the efficacy of 
hypofractionation and the use of SBRT (20). 
SBRT targeting macroscopic bladder tumor could differ 
from the conventional palliative treatment of the whole 
bladder in three critical ways: the treatment course is 
shortened; the target volume is reduced (partial bladder RT) 
and the daily dose is typically hypofractionated. The intent 
of this kind of intervention is to optimize symptom (and 
tumor!) control, minimizing bowel and urinary toxicities, 
and especially reduce OTT treatment augmenting patients’ 
compliance to RT. 
Clinical decisions for PRT in this particular setting 
of patients depends on different factors including 
comorbidities, stage, age and life expectancy, but a conscious 
patients’ selection should be followed by an accurate 
choice in RT modality. Encouraging data come from other 
palliative scenarios in oncology. For example, high-dose, 
single fraction SBRT has been recently showed in the 
prospective randomized phase II study, to offer higher rates 
of pain response and better local tumor control in patients 
treated for painful bone metastases than did conventionally 
fractionated RT delivered con standard techniques (21). 
We do believe that the combination of clinical parameters 
evaluation, together with the improvements in technologies 
could really increase the use of PRT and improve QoL in 
the management of incurable bladder cancer.  
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